title: Biosimilars approved for treatment of inflammatory rheumatological diseases.
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.|Australian Research Council Training Centre for Biopharmaceutical Innovation, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Mahler
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Andri
authors.initials: A
authors.lastname: Wardiana
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.|Australian Research Council Training Centre for Biopharmaceutical Innovation, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Martina L
authors.initials: ML
authors.lastname: Jones
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: de Bakker
authors.affiliation: School of Medical Sciences, St Vincent's Hospital, University of New South Wales and Department of Clinical Pharmacology, Sydney, New South Wales, Australia.
authors.forename: Garry G
authors.initials: GG
authors.lastname: Graham
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.|Australian Research Council Training Centre for Biopharmaceutical Innovation, University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Howard
mesh_terms: D059451:Biosimilar Pharmaceuticals; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*
chemical_list: D059451:Biosimilar Pharmaceuticals